ImmunoPrecise Antibodies Ltd. (OTCMKTS:IPATF – Get Free Report) shares traded down 10% during trading on Monday . The company traded as low as $1.5950 and last traded at $1.62. 854,332 shares were traded during trading, an increase of 4,103% from the average session volume of 20,327 shares. The stock had previously closed at $1.80.
ImmunoPrecise Antibodies Stock Down 10.0%
The firm’s 50 day moving average is $2.01 and its two-hundred day moving average is $1.99.
ImmunoPrecise Antibodies Company Profile
ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) is a Canada-based contract research organization specializing in the discovery and development of therapeutic antibodies. The company provides a full suite of preclinical research services, from target validation and lead identification through to humanization and optimization. Its capabilities encompass hybridoma, phage display, single B cell sorting and next-generation sequencing platforms to accelerate antibody candidate selection and characterization.
ImmunoPrecise serves biopharmaceutical and biotechnology partners worldwide, offering customized solutions for projects in immuno-oncology, infectious diseases, autoimmunity and other therapeutic areas.
See Also
- Five stocks we like better than ImmunoPrecise Antibodies
- Elon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)
- Forget AI, This Will Be the Next Big Tech Breakthrough
- Everyone’s watching Nvidia right now. Here’s why I’m excited.
- Trump’s new AI budget just passed — one stock could soar
- [How To] Invest Pre-IPO In SpaceX With $100!
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
